Engelmaier, Andrea Butterweck, Harald A Weber, Alfred
Published in
Immunotherapy
Immunodeficiency disorders can prevent your body from fighting infections. These disorders make it easier to catch viruses and bacterial infections caused by so-called pathogens. Patients suffering from immunodeficiencies are treated throughout their lives with antibodies purified from human plasma. This immunoglobulin replacement therapy, which he...
Corren, Jonathan Menzies-Gow, Andrew Bimmel, Johan McGuinness, Anthony Almqvist, Gun Bowen, Karin Griffiths, Janet M Ponnarambil, Sandhia Bourdin, Arnaud Israel, Elliot
...
Published in
Immunotherapy
This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the treatment of severe, uncontrolled asthma in people aged 12 and above. The results of these 2 studies, called PATHWAY and NAVIG...
Kawada, Tatsushi Yanagisawa, Takafumi Bekku, Kensuke Laukhtina, Ekaterina Deimling, Markus von Majdoub, Mohammed Chlosta, Marcin Pradere, Benjamin Babjuk, Marko Gontero, Paolo
...
Published in
Immunotherapy
Doctors use a medicine called BCG to treat a kind of bladder cancer that hasn't spread to other parts of the body. But because there isn't enough of this medicine, scientists are looking at giving smaller amounts. They found that smaller amounts of the medicine have fewer side effects, but they also found that they might not work as well to stop th...
Jeun, Rebecca Iyer, Priyanka C Best, Conor Lavis, Victor Varghese, Jeena M Yedururi, Sireesha Brady, Veronica Glitza Oliva, Isabella C Dadu, Ramona Milton, Denai R
...
Published in
Immunotherapy
Cancer treatment with immune checkpoint inhibitors can cause irreversible side effects. In this study, we describe the clinical presentations of 76 patients who developed immune checkpoint inhibitor diabetes mellitus, a rare complication of checkpoint inhibitor therapy that requires lifelong treatment with insulin therapy. Most patients presented w...
Zhu, Andrew X Lin, Yong Ferry, David Widau, Ryan C Saha, Abhijoy
Published in
Immunotherapy
This study was conducted to determine how effective measurements of tumor size are at predicting how long patients with liver cancer survive when they receive a drug that blocks proteins involved in immune system regulation, which are made by some types of immune system cells in the body. The authors calculated how closely measurements of a patient...
Razumikhin, Mikhail Smolyanova, Tatiana Nikolaeva, Alevtina Orlova, Ekaterina Ivanov, Aleksandr Belyakova, Olga Vyaznikova, Tatyana Selezneva, Natalia Perevozchikov, Anton Sokolova, Alina
...
Published in
Immunotherapy
An intravenous immunoglobulin with a high concentration of SARS-CoV-2-neutralizing antibodies was prepared from COVID-19 convalescent plasma, which could be utilized as a passive immunization tool in regard to COVID-19 treatment. The manufacturing process employed conforms to commonly held business standards within the intravenous immunoglobulin in...
Ma, Baozhen Zhao, Lingdi Zhang, Yong Zhang, Fang Gao, Quanli
Published in
Immunotherapy
Background: Ovarian clear cell carcinoma (OCCC), which is resistant to traditional treatment, has a poor prognosis. Immune checkpoint inhibitors (ICIs) have been emerged in the past decade and are now widely used in clinics. However, OCCC reportedly responds poorly to ICIs, and ICI monotherapy is rarely used for patients with OCCC. Methodology & Re...
Velaga, Ravi Koo, Kevin M Mainwaring, Paul N
Published in
Immunotherapy
Breast and prostate cancers are generally considered immunologically 'cold' tumors due to multiple mechanisms rendering them unresponsive to immune checkpoint blockade therapies. With little success in garnering positive outcomes in modern immunotherapeutic clinical trials, it is prudent to re-examine the role of immunogenic neoantigens in these co...
O'Connor, Cathal Finnegan, Paula Power, Derek G Bennett, Mary Bourke, John F
Published in
Immunotherapy
Pembrolizumab (trade name Keytruda®) is a type of immune therapy that stimulates the body's immune system to fight cancer cells. This immune therapy can cause a variety of rashes. In this article, we describe a patient who developed a red lumpy rash on her limbs that is not commonly described with pembrolizumab. A woman was diagnosed with advanced ...
Alalawi, Mai Bakr, Abrar Saeed Reda, Rowaida Sadak, Karim Thomas Nagy, Mohamad
Published in
Immunotherapy
Late-onset toxicities have been reported in cancer patients with monoclonal antibodies therapy and may involve several body organs or systems. They are defined as autoimmune illnesses that can happen months to years after treatment discontinuation. The reported late-onset toxicities include; bruises due to decreased platelet count associated with a...
